Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials
Authors: Mark G Lebwohl, Melinda Gooderham, Richard B Warren, Lawrence F Eichenfield, Jessica H Rubens, Tracy Cardillo, Christopher Russo, Cynthia M C DeKlotz, Megan Miller-Kassamali, Luis Anaya Velarde, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Sarah Ofori, Robert Bissonnette, Jennifer Soung, Adelaide A Hebert, Linda Stein Gold Read more on pubmed
EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study
Authors: Dehn, S., Cooper, D., Weyer, C., Ferguson, B., Srinivasan, S., Saint-Cyr Proulx, E., & Bissonnette, R. Read more on pubmed
Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis
Authors: LĂ©garĂ©, S., Lin, S., Vahey, S., Ovalles-Bonilla, J. G., D’Angelo, P., Jankicevic, J., & Bissonnette, R. Read more on pubmed
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials
Authors: Linda Stein Gold, April W Armstrong, Jennifer Soung, Ronald B Vender, Ălvaro GonzĂĄlez Cantero, Matthias Hoffmann, Scott T Guenthner, H Chih-Ho Hong, Dedee F Murrell, Eingun James Song, Leon Kircik, Matthias Augustin, Maxwell Sauder, Sascha Gerdes, Ofelia Reyes-Servin, Bassey Effiom Edem, Jennifer Campbell, Kellen Cresswell, Lea Kephart, Shu Li, Ya-Wen Yang, Robert Bissonnette Read […]
Ruxolitinib Cream Demonstrated Rapid Reductions in Itch and Atopic Dermatitis Signs That Correlated With Biomarkers
Authors: Bissonnette, R., Saint-Cyr Proulx, E., Correa da Rosa, J., Estrada, Y., Ren, H., Nawaz, H., Halden, P., Stefani-Hunyady, D., Popovic, K., Volkova, A., Smith, S. H., & Guttman-Yassky, E. Read more on pubmed
Characterizing the Burden of Hand Dermatitis in Canada: A Cross-Sectional Survey of Disease Impact
Authors: Cresswell-Melville, A., Mehta, S., Metko, D., Bissonnette, R., & Molin, S. Read more on pubmed
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
Authors: Warren, R. B., Gooderham, M., Lain, E., Bissonnette, R., Huang, Y. H., Ringuet, J., Hoffmann, M., Pinter, A., Merola, J. F., Rubens, J. H., Fan, D., Hsu, M. C., Li, S., Yang, Y. W., DeKlotz, C. M. C., & Song, E. J. Read more on pubmed
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD Study
Authors: Soung, J., Cui, Y., Bissonnette, R., Lebwohl, M. G., GonzĂĄlez-Cantero, Ă., Pinter, A., Rich, P., Prajapati, V. H., Miller-Kassamali, M., Cafone, J., Jiang, J., Li, S., Yang, Y. W., & Pink, A. E. Read more on pubmed
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement
Innovaderm/Indero founder Dr. Robert Bissonnette has coauthored the International Eczema Councilâs globally endorsed, expert-derived framework defining low disease activity and remission in atopic dermatitis, in JAMA Dermatology, April 2026. These standardized, clinically meaningful definitions provide a foundation for harmonized trial design, regulatory evaluation, and longitudinal comparative effectiveness research. Authors: Merola, J. F., Childs, B. A., Bartley, B. R., Bissonnette, R., Bieber, T., Guttman-Yassky, E., Paller, A. S., […]
Burden and Etiopathogenesis of Chronic Hand Eczema: A Complex Interplay of Genes, Environment, and Exposures
Authors: Molin, S., Yeung, J., & Bissonnette, R Different morphological and etiological subtypes of CHE appear to have overlapping and distinct features related to gene expression, proteomics, inflammatory biomarkers, and metagenomics, but data are limited and derived from small patient cohorts. The available evidence points to the broad activation of immune pathways implicated in JAK-STAT […]
